Travere Therapeutics Q1 Earnings Call Highlights

Key Points

• FDA approval: The FDA granted full approval for FILSPARI in focal segmental glomerulosclerosis (FSGS) — described as the first and only approved medicine for the condition — with a label for reducing proteinuria in patients eight years and older “without active nephrotic syndrome,” prompting strong KOL interest across FSGS subtypes.
• Commercial momentum: FILSPARI demand reached a record in Q1 with 993 new patient start forms (pre‑FSGS approval) and U.S. net sales of $105.2 million (up ~88% YoY), while management reports >97% payer access and expects faster uptake in FSGS versus the earlier IgA nephropathy launch.
• Pipeline and finances: Travere restarted enrollment in the phase III HARMONY study of pegtibatinase for classical homocystinuria and targets top-line results in 2H 2027, and the company ended Q1 with about $352 million in cash, marketable securities, and receivables despite a GAAP net loss of $37.1 million (non‑GAAP net income $4.1 million).

Travere Therapeutics NASDAQ: TVTX executives highlighted a first-quarter marked by an FDA approval, record demand for FILSPARI in IgA nephropathy, and renewed progress in the company’s late-stage pipeline, according to remarks on the company’s first quarter 2026 financial results call.

FDA approval expands FILSPARI into FSGS

President and CEO Eric Dube said April 13 “marked a pivotal point” for patients with focal segmental glomerulosclerosis (FSGS) after the FDA granted a full approval for FILSPARI. Dube called it “the first and only approved medicine” for the condition and said the label expansion “meaningfully increases the opportunity ahead” for the company.

Chief Medical Officer Dr. Jula Inrig said FILSPARI was approved “to reduce proteinuria in adults and children eight years and older with FSGS without nephrotic syndrome.” She also spent time clarifying how nephrotic syndrome is assessed in practice and how that relates to eligibility, emphasizing that nephrotic syndrome is “typically defined” by three criteria—proteinuria above 3.5 g/day, low serum albumin, and edema—and that if a patient is missing any one, “they are not considered to have active nephrotic syndrome.”

Inrig added that this differs from “nephrotic range proteinuria,” noting that some patients with high proteinuria could still be eligible if other criteria are not present. She also said nephrotic syndrome “is not a chronic state,” and described how patients who initially present with nephrotic syndrome may become eligible after induction therapy.

Following the FDA action, Inrig said discussions with key opinion leaders reflected “wide enthusiasm” for using FILSPARI “across the types of FSGS, including among secondary and genetic FSGS,” citing a recent CJASN publication that she said demonstrated consistent efficacy and safety in genetic FSGS.

IgA nephropathy demand reaches new highs

Travere reported another record quarter of demand for FILSPARI in IgA nephropathy, with Chief Commercial Officer Peter Heerma reporting 993 new patient start forms (PSFs) in the first quarter. Heerma attributed the performance to continued expansion among new prescribers and increased use within existing accounts, adding that the company is seeing “an increasing number of practices treating multiple IgA nephropathy patients with FILSPARI.”

Heerma also said that, as more options become available in IgA nephropathy, FILSPARI “remains the most commonly prescribed medicine approved for IgA nephropathy in the U.S.” He described demand early in the second quarter as strong.

In Q&A, the company said it would not provide guidance on the FSGS launch pace or break out PSFs by indication going forward. Dube clarified that the 993 PSFs reported for the first quarter were generated prior to the FSGS approval and therefore reflected IgA nephropathy performance.

Asked about patient persistence in IgA nephropathy, Heerma said compliance and persistence have been “very high,” without providing specific rates. Inrig said persistence appears consistent with what was observed in the two-year double-blind PROTECT trial and attributed durability to patients seeing proteinuria improvements and a side effect profile she described as consistent with irbesartan. Inrig added that patients understand FILSPARI should be “truly” long-term therapy “as long as they keep their kidneys.”

Early FSGS launch commentary centers on awareness, access, and education

Heerma said the company expects a faster uptake in FSGS than in IgA nephropathy, citing high unmet need, physician familiarity with FILSPARI from IgA nephropathy, and payer positioning. He said Travere has “over 97% access” and described early feedback from the community as “overwhelmingly positive,” including receiving patient start forms the day after approval and seeing reimbursement approvals within the first week.

While the company declined to quantify early FSGS PSFs during the call, Heerma said early experience has “confirm[ed]” expectations of faster uptake and “a higher first pass approval at the payer level than what we saw initially for IgA.”

Executives also emphasized physician education, particularly around the label’s “without nephrotic syndrome” language. Heerma said some community nephrologists “may not know yet that FILSPARI was approved,” and that education is needed to explain nephrotic syndrome concepts. Inrig added that the community has been waiting “a long time” for a non-immunosuppressive option and reiterated that “active nephrotic syndrome is not the same as nephrotic range proteinuria.”

On questions about whether a history of nephrotic syndrome could limit use, Inrig said the company does not believe it should, emphasizing the label is for patients “without active nephrotic syndrome.” Heerma said payers understand nephrotic syndrome is “a dynamic state” and said the topic has not been a major issue in discussions to date.

When asked about treatment sequencing in FSGS, Inrig said most patients are already on an ACE inhibitor or ARB by the time they see a nephrologist—“more than 70%, at least 80%”—and that physicians may also use SGLT2 inhibitors, though she characterized usage as less prevalent due to less robust data in FSGS. She added that, given FILSPARI’s head-to-head positioning versus RAS inhibition, physicians are expected to take patients off a RAS inhibitor and initiate FILSPARI.

Pegtibatinase program restarts enrollment; top-line results targeted for 2H 2027

Travere also highlighted progress in its pipeline with pegtibatinase in classical homocystinuria (HCU). Dube said the company dosed the first new patient in the phase III HARMONY study following a restart of enrollment, and he said the company remains on track to report top-line results in the second half of 2027.

Inrig said HARMONY is a randomized, double-blind study comparing pegtibatinase to placebo with a primary endpoint focused on reduction in plasma total homocysteine assessed at 12 weeks, consistent with the timing used in the phase I/II COMPOSE study. She said COMPOSE demonstrated “rapid, sustained, and dose-dependent reductions” in total homocysteine and cited a 67.1% mean relative reduction at 12 weeks at a 2.5 mg/kg twice-weekly dose, along with maintenance below 100 micromoles and generally good tolerability.

Chief Research Officer Dr. Bill Rote said pegtibatinase has breakthrough therapy designation, enabling frequent FDA interaction, and that Travere aligned with the agency on the HARMONY endpoint through a “collaborative discussion.” He added there has been no need to revisit endpoints since alignment was reached.

Financial results: revenue growth, higher spending, and cash runway

Chief Financial Officer Chris Cline reported $124.5 million in total U.S. net product sales for the first quarter, with FILSPARI U.S. net product sales of $105.2 million, up about 88% year-over-year. Cline said results were achieved despite typical beginning-of-year gross-to-net dynamics and “one fewer shipping week than usual,” which he said would shift some revenue recognition into the second quarter.

THIOLA and THIOLA EC contributed $19.3 million in U.S. net product sales, and Travere recognized $2.7 million in license and collaboration revenue, bringing total revenue to $127.2 million.

Operating expenses increased year-over-year, with R&D expense of $57.1 million (non-GAAP adjusted $51.5 million), which Cline said was driven primarily by the restart of enrollment in HARMONY. SG&A expense rose to $80.3 million (non-GAAP adjusted $69.3 million), which he attributed primarily to investments ahead of the FILSPARI launch in FSGS and continued investments in IgA nephropathy.

Travere also revised its presentation of amortization associated with royalty and milestone payments into a separate royalty expense line item. Royalty expense was $24.8 million, up from $12.4 million in the year-ago quarter, which Cline said was mainly due to the THIOLA intangible asset reaching the end of its accounting useful life and increased capitalized FILSPARI royalties.

The company posted a GAAP net loss of $37.1 million, or $0.40 per basic share, compared with a net loss of $41.2 million, or $0.47 per basic share, in the first quarter of 2025. On a non-GAAP adjusted basis, Travere reported net income of $4.1 million, or $0.05 per basic share, versus a non-GAAP adjusted net loss of $16.9 million, or $0.19 per basic share, a year earlier.

As of March 31, 2026, Travere had approximately $352 million in cash equivalents, marketable securities, and receivables. Cline noted receivables included a $25 million sales-based milestone payment from Mirum Pharmaceuticals that was recognized in the fourth quarter of 2025 and received in April. He said the company is “well-positioned to fund” operations with existing resources.

About Travere Therapeutics NASDAQ: TVTX

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.